MannKind Corporation 2014 Form 10-K Summary
Business context and reporting period
MannKind is a biopharmaceutical company focused on diabetes therapies. The filing covers the fiscal year ended December 31, 2014, including fourth-quarter activity. AFREZZA, the company’s rapid-acting inhaled insulin, received FDA approval on June 27, 2014. Sanofi became responsible for global development, regulatory and commercialization activities under an agreement effective September 23, 2014, while MannKind retained primary manufacturing responsibility.
Financial performance and position
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Net loss | $198.4 million | $191.5 million | Loss increased $6.9 million |
| Net loss per share | $0.51 | $0.64 | Improved, primarily due to higher share count |
| Operating expenses | $179.6 million | $169.4 million | Increased $10.2 million |
| Research and development | $100.2 million | $109.7 million | Decreased 9% |
| General and administrative | $79.4 million | $59.7 million | Increased 33% |
| Net cash from operating activities | $4.1 million | $(128.7) million | Improved $132.8 million |
| Capital expenditures | $24.1 million | $8.0 million | Increased $16.1 million |
| Cash and cash equivalents | $120.8 million | $70.8 million | Increased $50.1 million |
No meaningful margin was reported because the company had no revenue. The accumulated deficit was $2.5 billion and stockholders’ deficit was $73.8 million at year-end. Total assets were $394.4 million, including $192.1 million of property and equipment, $9.7 million of inventory and $50.4 million of collaboration receivables.
Principal debt totaled $229.5 million: $100.0 million of 5.75% convertible notes due August 2015, $60.0 million of 9.75% notes due in installments from 2016 through 2019, $20.0 million of 8.75% Tranche B notes due through 2019, and $49.5 million owed under the Mann Group loan arrangement. A Sanofi secured loan facility allowed up to $175.0 million of borrowings to fund MannKind’s share of collaboration losses; $3.0 million was borrowed after year-end.
Material changes versus the prior comparable period
- Sanofi paid a $150.0 million upfront amount and MannKind earned an additional $50.0 million manufacturing milestone. Neither amount was recognized as revenue because the loss-sharing arrangement prevented the consideration from being considered fixed and determinable. The amounts were recorded as deferred collaboration payments or receivables.
- Operating cash flow improved to $4.1 million from a $128.7 million outflow, principally because of the deferred Sanofi upfront payment. This improvement does not represent recurring operating profitability.
- R&D expense declined as two AFREZZA Phase 3 studies were completed in 2013, partly offset by higher manufacturing preparation costs and stock-based compensation.
- G&A expense increased primarily from Sanofi transaction costs, Facility Agreement amendments, professional fees, milestone-related compensation and severance.
- Deerfield converted $93.5 million of 2019-note principal into 17.3 million common shares. MannKind also raised cash through $40.0 million of additional 2019 notes, $20.0 million of Tranche B notes, warrant exercises and stock-option exercises.
- Commercial manufacturing began in the latter part of the fourth quarter. Manufacturing capacity was expected to increase from approximately 100–120 million cartridges annually to 300–360 million after qualification of two additional filling lines.
Guidance, outlook, risks and unusual items
- Management expected 2015 R&D and G&A expenses to decrease, but expected continued significant spending on commercial manufacturing, AFREZZA support and other product opportunities.
- AFREZZA became available by prescription in U.S. retail pharmacies on February 3, 2015. The filing provides no quantified sales guidance or revenue forecast.
- The FDA required post-marketing studies, including pediatric studies, pharmacokinetic/pharmacodynamic studies and a five-year controlled study of 8,000–10,000 type 2 diabetes patients addressing pulmonary malignancy risk and other long-term safety matters.
- The company depends heavily on Sanofi’s commercialization performance, foreign regulatory approvals, market acceptance, reimbursement and Sanofi’s willingness to devote adequate resources to AFREZZA.
- MannKind had limited commercial manufacturing experience and relied on a single approved insulin source, Amphastar. The insulin agreement required minimum purchases of approximately €120.1 million for 2015–2019, including a $15.0 million prepayment for 2015 supply.
- The company disclosed substantial doubt about its ability to continue as a going concern because of recurring losses, negative cumulative operating cash flow, the $100.0 million 2015-note maturity and dependence on refinancing or additional financing. The auditor issued an unqualified opinion with an explanatory going-concern paragraph.
- Debt agreements included secured interests in substantially all assets, financial covenants, restrictions on additional borrowing and potential acceleration upon defaults. The Facility Agreement required cash and available qualifying borrowings of at least $25.0 million at quarter-end.
- Unusual 2014 items included $7.9 million of net other income from an oncology intellectual-property sale, a $6.4 million non-cash charge on debt conversions, a $1.8 million write-off of an unused Tranche B commitment asset and $48.6 million of stock-based compensation.
- No material off-balance-sheet arrangements or material litigation accruals were reported. Management and the auditor concluded internal control over financial reporting was effective.
Most important facts for investors to verify
- Whether AFREZZA prescriptions, net sales, reimbursement access and Sanofi’s commercial investment are sufficient to generate sustainable profit-sharing cash flows.
- How the $100.0 million 2015-note maturity was refinanced, converted or repaid after August 15, 2015.
- Actual borrowings and repayment terms under the Sanofi Loan Facility, including the effect of collaboration losses on secured debt.
- Progress, results and potential labeling or commercial consequences of the FDA-required post-marketing safety studies.
- Manufacturing scale-up, product quality, insulin supply continuity and compliance at MannKind and third-party suppliers.
- Compliance with debt covenants and the company’s ability to obtain additional capital without substantial dilution or unfavorable security interests.
- Revenue-recognition treatment and timing for the deferred $150.0 million upfront payment and $50.0 million milestone payment.